Clinical relevance of FASII bypass in Staphylococcus aureus - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Antimicrobial Agents and Chemotherapy Année : 2017

Clinical relevance of FASII bypass in Staphylococcus aureus

Résumé

The need for new antimicrobials to treat bacterial infections has led to the use of fatty acid synthesis (FASII) enzymes as front-line targets. However, recent studies suggest that FASII inhibitors may not work against the opportunist pathogen Staphylococcus aureus, as environmental fatty acids favor emergence of multi-anti-FASII resistance. As fatty acids are abundant in the host, and one FASII inhibitor, triclosan, is widespread, we investigated whether fatty acid pools impact resistance in clinical and veterinary S. aureus isolates. Simple addition of fatty acids to screening medium led to a 50% increase in triclosan resistance, as tested in 700 isolates. Moreover, non-culturable triclosan-resistant fatty acid auxotrophs, which escape detection under routine conditions, were uncovered in primary patient samples. FASII bypass in selected isolates correlated with polymorphisms in acc and fabD loci. We conclude that fatty-acid-dependent strategies to escape FASII inhibition are common among S. aureus isolates and correlate with anti-FASII resistance and emergence of non-culturable variants.

Mots clés

Dates et versions

hal-02195054 , version 1 (26-07-2019)

Identifiants

Citer

Karine Gloux, Mélanie Guillemet, Charles Soler, Claire Morvan, David Halpern, et al.. Clinical relevance of FASII bypass in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2017, 61 (5), ⟨10.1128/AAC.02515-16⟩. ⟨hal-02195054⟩
146 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More